The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer

Nutrition and Metabolism

Volumn 9, Issue , 2012, Pages

  Melnik, Bodo C ^a   John, Swen Malte ^a   Carrera Bastos, Pedro ^b   Cordain, Loren ^c  

^a UNIVERSITY OF OSNABRÜCK   (Germany)

^b LUND UNIVERSITY   (Sweden)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Cancer prevention; Dairy; Estrogens; IGF 1; Insulin; Leucine; Metformin; Milk signaling; Morphogenesis; mTORC1; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; BRANCHED CHAIN AMINO ACID; GUANOSINE TRIPHOSPHATASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; METFORMIN;

ADIPOGENESIS; ARTICLE; AUTOPHAGY; BLOOD LEVEL; BREAST MILK; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CHEESE; DISEASE COURSE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOGENESIS; MALE; MEAT; META ANALYSIS (TOPIC); MILK; MORPHOGENESIS; MORTALITY; NEWBORN PERIOD; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORGANOGENESIS; POSTNATAL GROWTH; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN INTAKE; RAPTOR; RISK FACTOR; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 84864914359     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-9-74     Document Type: Article

References (273)

1. Globocan (2008) Prostate cancer incidence and mortality worldwide in 2008 summary 2008 http://globocan.oarc.fr/factsheets/cancers/prostate.asp. Accessed 05/2012
2. World Cancer Research Fund/American Institute for Cancer Research (2007) Food, Nutrition, Physical Activity, and the Prevention of Cancer, A Global Perspective American Institute for Cancer Research, Washington, DC 2007 http://www.scribd.com/doc/28815788/Food-Nutrition-Physical-Activity-and-the Prevention-of-Cancer-a-Global-Perspective
3. Impact of diet on prostate cancer: a review. Sonn GA, Aronson W, Litwin MS, Prostate Cancer Prostatic Dis 2005 8 304 310 10.1038/sj.pcan.4500825 16130015 (Pubitemid 43078163)
4. Diet and prostate cancer prevention. Marshall JR, World J Urol 2012 30 157 165 10.1007/s00345-011-0810-0 22249340
5. Diet and prostate cancer risk reduction. Cheung E, Wadhera P, Dorff T, Pinski J, Expert Rev Anticancer Ther 2008 8 43 50 10.1586/14737140.8.1.43 18095882
6. Incidence and mortality of testicular and prostatic cancers in relation to world dietary practices. Ganmaa D, Li XM, Wang J, Qin LQ, Wang PY, Sato A, Int J Cancer 2002 98 262 267 10.1002/ijc.10185 11857417 (Pubitemid 34150811)
7. International comparisons of prostate cancer mortality rates with dietary practices and sunlight levels. Colli JL, Colli A, Urol Oncol 2006 24 194 194
8. The experience of Japan as a clue to the etiology of testicular and prostatic cancers. Ganmaa D, Li XM, Qin LQ, Wang PY, Takeda M, Sato A, Med Hypotheses 2003 60 724 730 10.1016/S0306-9877(03)00047-1 12710911 (Pubitemid 36399307)
9. A prospective study of calcium intake and incident and fatal prostate cancer. Giovannucci E, Liu Y, Stampfer MJ, Willett WC, Cancer Epidemiol Biomarkers Prev 2006 15 203 210 10.1158/1055-9965.EPI-05-0586 16492906 (Pubitemid 43342165)
10. Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Tjønneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Bueno-de-Mesquita HB, Kiemeney L, Tagliabue G, Palli D, Vineis P, Tumino R, Trichopoulou A, Kassapa C, Trichopoulos D, Ardanaz E, Larrãaga N, Tormo MJ, González CA, Quirás JR, Sánchez MJ, Bingham S, Khaw KT, Manjer J, Berglund G, Stattin P, Hallmans G, Slimani N, Ferrari P, Rinaldi S, Riboli E, Br J Cancer 2008 98 1574 1581 10.1038/sj.bjc.6604331 18382426 (Pubitemid 351652328)
11. Dairy products, calcium intake, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Ahn J, Albanes D, Peters U, Schatzkin A, Lim U, Freedman M, Chatterjee N, Andriole GL, Leitzmann MF, Hayes RB, Prostate, Lung, Colorectal, and Ovarian Trial Project Team, Cancer Epidemiol Biomarkers Prev 2007 16 2623 2630 10.1158/1055-9965.EPI- 07-0601 18086766 (Pubitemid 351196317)
12. Calcium, dairy, and prostate cancer. Heaney RP, Br J Cancer 2007 96 6 1008 10.1038/sj.bjc.6603680 17342083 (Pubitemid 46452296)
13. Dairy products, calcium, phosphorus, vitamin D, and risk of prostate cancer (Sweden). Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A, Cancer Causes Control 1998 9 559 566 10.1023/A:1008823601897 10189041 (Pubitemid 29046128)
14. Dairy products, calcium, and prostate cancer risk in the Physicians Health Study. Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL, Am J Clin Nutr 2001 74 549 554 11566656 (Pubitemid 32880268)
15. Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Tseng M, Breslow RA, Graubard BI, Ziegler RG, Am J Clin Nutr 2005 81 1147 1154 15883441 (Pubitemid 41724958)
16. Dairy products, calcium and phosphorus intake, and the risk of prostate cancer: results of the French prospective SU.VI.MAX (Supplémentation en Vitamines etMinnéraux Antioxydants) study. Kesse E, Bertrais S, Astorg P, Jaouen A, Arnault N, Galan P, Hercberg S, Br J Nutr 2006 95 539 545 10.1079/BJN20051670 16512941
17. Lactase persistence, dietary intake of milk, and the risk for prostate cancer in Sweden and Finland. Torniainen S, Hedelin M, Autio V, Rasinperä H, Augustsson Bälter K, Kint A, Bellocco R, Wiklund F, Stattin P, Ikonen T, Tammela TL, Schleutker J, Grönberg H, Järvelä I, Cancer Epidemiol Biomarkers Prev 2007 16 956 961 10.1158/1055-9965.EPI-06-0985 17507622 (Pubitemid 46915311)
18. Calcium, vitamin D, and dairy product intake and prostate cancer risk. The Multiethnic Cohort Study. Park SY, Murphy SP, Wilkens LR, Stram DO, Henderson BE, Kolonel LN, Am J Epidemiol 2007 166 1259 1269 10.1093/aje/kwm269 17925283 (Pubitemid 350129426)
19. A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland). Mitrou PN, Albanes D, Weinstein SJ, Pietinen P, Taylor PR, Virtamo J, Leitzmann MF, Int J Cancer 2007 120 2466 2473 10.1002/ijc.22553 17278090 (Pubitemid 46642136)
20. Dairy product, saturated fatty acid, and calcium intake and prostate cancer in a prospective cohort of Japanese men. Kurahashi N, Inoue M, Iwasaki M, Sasazuki S, Tsugane AS, Japan Public Health Center-Based Prospective Study Group, Cancer Epidemiol Biomarkers Prev 2008 17 930 937 10.1158/1055-9965.EPI- 07-2681 18398033 (Pubitemid 351536425)
21. Diet and prostate cancer risk with specific focus on dairy products and dietary calcium: a case-control study. Raimondi S, Mabrouk JB, Shatenstein B, Maisonneuve P, Ghadirian P, Prostate 2010 70 1054 1065 10.1002/pros.21139 20232354
22. Milk consumption is a risk factor for prostatic cancer: meta-analysis of case-control studies. Qin LQ, Xu JY, Wang PY, Kaneko T, Hoshi K, Sato A, Nutr Cancer 2004 48 22 27 10.1207/s15327914nc4801-4 15203374 (Pubitemid 38823543)
23. Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. Gao X, LaValley MP, Tucker KL, J Natl Cancer Inst 2005 97 1768 1777 10.1093/jnci/dji402 16333032 (Pubitemid 41782286)
24. Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. Qin LQ, Xu JY, Wang PY, Tong J, Hoshi K, Asia Pac J Clin Nutr 2007 16 467 476 17704029 (Pubitemid 47463625)
25. A systematic review of the effect of diet in prostate cancer prevention and treatment. Ma RW, Chapman K, J Hum Nutr Diet 2009 22 187 199 10.1111/j.1365-277X.2009.00946.x 19344379
26. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of the United States men. Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, Fakhrabadi-Shokoohi D, Giovannucci EL, Thun MJ, Calle EE, Cancer Epidemiol Biomarkers Prev 2003 12 597 603 12869397 (Pubitemid 36899838)
27. Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Huncharek M, Muscat J, Kupelnick B, Nutr Cancer 2008 60 421 441 10.1080/01635580801911779 18584476 (Pubitemid 351918540)
28. Inuit are protected against prostate cancer. Dewailly E, Mulvad G, Pedersen HS, Hansen JC, Behrendt N, Hansen JP, Cancer Epidemiol Biomarkers Prev 2003 12 926 927 14504206 (Pubitemid 37151531)
29. Prostate cancer in Alaska native men, 1969-2003. Snyder OB, Kelly JJ, Lanier AP, Int J Circumpolar Health 2006 65 8 17 16544643
30. Milk intake in early life and risk of advanced prostate cancer. Torfadottir JE, Steingrimsdottir L, Mucci L, Aspelund T, Kasperzyk JL, Olafsson O, Fall K, Tryggvadottir L, Harris TB, Launer L, Jonsson E, Tulinius H, Stampfer M, Adami HO, Gudnason V, Valdimarsdottir UA, Am J Epidemiol 2012 175 144 153 10.1093/aje/kwr289 22190107
31. High school dietary intake and acne. Adebamowo CA, Spiegelman D, Danby FW, Frazier AL, Willett WC, Holmes MD, J Am Acad Dermatol 2005 52 207 211 10.1016/j.jaad.2004.08.007 15692464
32. Milk consumption and acne in adolescent girls. Adebamowo CA, Spiegelman D, Berkey CS, Danby FW, Rockett HH, Colditz GA, Willett WC, Holmes MD, Dermatology Online J 2006 12 1 12
33. Milk consumption and acne in teenaged boys. Adebamowo CA, Spiegelman D, Berkey CS, Danby FW, Rockett HH, Colditz GA, Willett WC, Holmes MD, J Am Acad Dermatol 2008 58 787 793 10.1016/j.jaad.2007.08.049 18194824
34. The influence of dietary patterns on acne vulgaris in Koreans. Jung JY, Yoon MY, Min SU, Hong JS, Choi YS, Suh DH, Eur J Dermatol 2010 20 768 772 20822969
35. Evidence for acne-promoting effects of milk and other insulinotropic dairy products. Melnik BC, Nestle Nutr Workshop Ser Pediatr Program 2011 67 131 145 21335995
36. Acne and risk of prostate cancer. Sutcliffe S, Giovannucci E, Isaacs WB, Willett WC, Platz EA, Int J Cancer 2007 121 2688 2692 10.1002/ijc.23032 17724724 (Pubitemid 350136413)
37. Dietary intervention in acne: attenuation of increased mTORC1 signaling promoted by Western diet. Melnik BC, Dermatoendocrinology 2012 4 1 10.4161/derm.20016
38. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Giovannucci E, Cancer Causes Control 1998 9 567 582 10.1023/A:1008835903714 10189042 (Pubitemid 29046129)
39. Dairy products, calcium and prostate cancer risk. Koh KA, Sesso HD, Paffenbarger RS, Lee IM, Br J Cancer 2006 95 1582 1585 10.1038/sj.bjc.6603475 17106437 (Pubitemid 44863364)
40. Dairy products and prostate cancer risk. Newmark HL, Heaney RP, Nutr Cancer 2010 62 297 299 10.1080/01635580903407221 20358466
41. Milk stimulates growth of prostate cancer cells in culture. Tate PL, Bibb R, Larcom LL, Nutr Cancer 2011 63 1361 1366 10.1080/01635581.2011.609306 22043817
42. Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death. Pettersson A, Kasperzyk JL, Kenfield SA, Richman EL, Chan JM, Willett WC, Stampfer MJ, Mucci LA, Giovannucci EL, Cancer Epidemiol Biomarkers Prev 2012 21 428 436 10.1158/1055-9965.EPI-11-1004 22315365
43. The mTOR signalling pathway in human cancer. Pápulo H, Lopes JM, Soares P, Int J Mol Sci 2012 13 1886 1918 10.3390/ijms13021886 22408430
44. Signaling by target of rapamycin proteins in cell growth control. Inoki K, Ouyang H, Li Y, Guan KL, Microbiol Mol Biol Rev 2005 69 79 100 10.1128/MMBR.69.1.79-100.2005 15755954 (Pubitemid 40358068)
45. The two TORCs and Akt. Bhaskar PT, Hay N, Develop Cell 2007 12 487 502 10.1016/j.devcel.2007.03.020 (Pubitemid 46523652)
46. Nutrient control of TORC1, a cell-cycle regulator. Wang X, Proud CG, Cell 2009 19 260 267
47. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Sengupta S, Peterson TR, Sabatini DM, Mol Cell 2010 40 310 322 10.1016/j.molcel.2010.09.026 20965424
48. Spatial regulation of the mTORC1 system in amino acids sensing pathway. Suzuki T, Inoki K, Acta Biochim Biophys Sin 2011 43 671 679 10.1093/abbs/gmr066 21785113
49. mTORC1 signaling: what we still dont know. Wang X, Proud CG, J Mol Cell Biol 2011 3 206 220 10.1093/jmcb/mjq038 21138990
50. LKB1 and AMPK control of mTOR signalling and growth. Shaw RJ, Acta Physiol(Oxf.) 2009 196 65 80 10.1111/j.1748-1716.2009.01972.x
51. Amino acid regulation of TOR complex 1. Avruch J, Long X, Ortiz-Vega S, Rapley J, Papageorgiou A, Dai N, Am J Physiol Endocrinol Metab 2009 296 592 602 10.1152/ajpendo.90645.2008
52. Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. Kimball SR, Jefferson LS, J Nutr 2006 136 227S 231S 16365087 (Pubitemid 43156513)
53. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM, Science 2008 320 1496 1501 10.1126/science.1157535 18497260 (Pubitemid 351929429)
54. Leucine and mTORC1: a complex relationship. Dodd KM, Tee AR, Am J Physiol Endocrinol Metab 2012 302 1329 E1342 10.1152/ajpendo.00525.2011 22354780
55. Ragulator- Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S, Sabatini DM, Cell 2010 141 290 303 10.1016/j.cell.2010.02. 024 20381137
56. Intracellular amino acid sensing and mTORC1-regulated growth: New ways to block an old target? Goberdhan DC, Curr Opin Invest Drugs 2010 11 1360 1367
57. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Inoki K, Li Y, Zhu T, Wu J, Guan KL, Nat Cell Biol 2002 4 648 657 10.1038/ncb839 12172553 (Pubitemid 34993700)
58. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide-3-kinase/akt pathway. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC, Mol Cell 2002 10 151 162 10.1016/S1097-2765(02)00568-3 12150915 (Pubitemid 34876569)
59. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J, Proc Natl Acad Sci USA 2001 99 13571 13576 (Pubitemid 35215423)
60. TSC2 mediates cellular energy response to control cell growth and survival. Inoki K, Zhu T, Guan KL, Cell 2003 115 577 590 10.1016/S0092-8674(03) 00929-2 14651849 (Pubitemid 37506046)
61. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ, Mol Cell 2008 30 214 226 10.1016/j.molcel.2008.03.003 18439900 (Pubitemid 351626684)
62. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4EBP1 through a common effector mechanism. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J, J Biol Chem 1998 273 14484 14494 10.1074/jbc.273.23.14484 9603962 (Pubitemid 28319170)
63. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. Long X, Ortiz-Vega S, Lin Y, Avruch J, J Biol Chem 2005 280 23433 23436 10.1074/jbc.C500169200 15878852 (Pubitemid 40884818)
64. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Nobukuni T, Joaquin M, Roccio M, Dann SG, Kim SY, Gulati P, Byfield MP, Backer JM, Natt F, Bos JL, Zwartkruis FJ, Thomas G, Proc Natl Acad Sci USA 2005 102 14238 14243 10.1073/pnas.0506925102 16176982 (Pubitemid 41429682)
65. Mechanisms involved in the coordinate regulation of mTORC1 by insulin and amino acids. Dennis MD, Baum JI, Kimball SR, Jefferson LS, J Biol Chem 2011 286 8287 8296 10.1074/jbc.M110.209171 21239491
66. A new player in the orchestra of cell growth: SREBP activity is regulated by mTORC1 and contributes to the regulation of cell and organ size. Porstmann T, Santos CR, Lewis C, Griffiths B, Schulze A, Biochem Soc Trans 2009 37 278 283 10.1042/BST0370278 19143646
67. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, Guertin DA, Madden KL, Carpenter AE, Finck BN, Sabatini DM, Cell 2011 146 408 420 10.1016/j.cell.2011.06.034 21816276
68. mTOR: from growth signal integration to cancer, diabetes and ageing. Zoncu R, Efeyan A, Sabatini DM, Nature Rev 2011 12 21 35 10.1038/nrm3025
69. mTOR signalling in health and disease. Proud CG, Biochem Soc Trans 2011 39 431 436 10.1042/BST0390431 21428914
70. Tuberous sclerosis complex: liking cancer to metabolism. Mieulet V, Lamb RF, Trends Mol Med 2010 16 329 335 10.1016/j.molmed.2010.05.001 20605525
71. mTOR Complex 1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Dann SG, Selvaraj A, Thomas G, Trends Mol Med 2007 13 252 259 10.1016/j.molmed.2007.04.002 17452018 (Pubitemid 46836871)
72. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Shaw RJ, Cantley LC, Nature 2006 441 424 430 10.1038/nature04869 16724053 (Pubitemid 44050136)
73. Akt-regulated pathways in prostate cancer. Majumder PK, Sellers WR, Oncogene 2005 24 7465 7474 10.1038/sj.onc.1209096 16288293 (Pubitemid 41637986)
74. mTOR and cancer therapy. Easton JB, Houghton PJ, Oncogene 2006 25 6436 6446 10.1038/sj.onc.1209886 17041628 (Pubitemid 44582287)
75. Mutation and expression analysis of the putative prostate tumour- suppressor gene PTEN. Gray IC, Stewart LM, Phillips SM, Hamilton JA, Gray NE, Watson GJ, Spurr NK, Snary D, Br J Cancer 1998 78 1296 1300 10.1038/bjc.1998.674 9823969 (Pubitemid 28495240)
76. Integrative genomic profiling of human prostate cancer. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Golgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerlad WL, for the MSKCC Prostate Cancer Oncogenome Group (PCOG), Cancer Cell 2010 18 11 22 10.1016/j.ccr.2010.05.026 20579941
77. Nutrient overload, insulin resistance, and ribosomal S6 kinase, S6K1. Um SH, D'Alessio D, Thomas G, Cell Metab 2006 3 393 402 10.1016/j.cmet.2006.05.003 16753575 (Pubitemid 43811780)
78. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Inoki K, Li Y, Xu T, Guan KL, Genes Dev 2003 17 1829 1834 10.1101/gad.1110003 12869586 (Pubitemid 36944560)
79. Rheb binds and regulates the mTOR kinase. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J, Curr Biol 2005 15 702 713 10.1016/j.cub.2005.02.053 15854902 (Pubitemid 40599924)
80. Negative regulation of PKB/Akt- dependent cell survival by the tumor suppressor PTEN. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW, Cell 1998 95 29 39 10.1016/S0092-8674(00)81780-8 9778245 (Pubitemid 28458022)
81. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL, Proc Natl Acad Sci USA 1998 95 5246 5250 10.1073/pnas.95.9.5246 9560261 (Pubitemid 28208583)
82. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP, Nat Genet 2001 27 222 224 10.1038/84879 11175795 (Pubitemid 32157454)
83. Pten dose dictates cancer progression in the prostate. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP, PLoS Biol 2003 1 3 59 14691534
84. mTOR, translation initiation and cancer. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N, Oncogene 2006 25 6416 6422 10.1038/sj.onc.1209888 17041626 (Pubitemid 44582285)
85. The mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen J-H, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM, Cancer Cell 2009 15 148 159 10.1016/j.ccr.2008.12.017 19185849
86. Differential requirement of mTOR in post-mitotic tissues and tumorigenesis. Nardella C, Carracedo A, Altimonti A, Hobbs RM, Clohessy JG, Chen Z, Egia A, Fornari A, Fiorentino M, Loda M, Kozma SC, Thomas G, Cordon-Cardo C, Pandolfi PP, Sci Signal 2010 2 55 a2 10.1126/scisignal.2000189
87. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Furic L, Rong L, Larsson O, Hervé Koumakpayi I, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, Pandolfi PP, Saad F, Sonenberg N, Proc Natl Acad Sci USA 2010 107 14134 14139 10.1073/pnas.1005320107 20679199
88. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C, Pandolfi PP, Genes Dev 2008 22 2172 2177 10.1101/gad.1699608 18708577
89. Found in translation of mTOR signaling. Clohessy JG, Reschke M, Pandolfi PP, Cell Res 2012 1 4 May 29, doi:10.1038/cr.2012.85
90. A unifying model for mTORC1-mediated regulation of mRNA translation. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM, Nature 2012 485 109 116 10.1038/nature11083 22552098
91. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D, Nature 2012 485 55 64 10.1038/nature10912 22367541
92. The deficiency of Akt 1 is sufficient to suppress tumor development in Pten+/- mice. Chen ML, Xu PZ, Peng XD, Chen WS, Guuzman G, Yang Y, Di Cristofano A, Pandolfoi PP, Hay N, Genes Develop 2006 20 1569 1574 10.1101/gad.1395006 16778075 (Pubitemid 43901096)
93. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1 dependent pathways. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarollas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR, Nat Med 2004 10 594 601 10.1038/nm1052 15156201 (Pubitemid 38796850)
94. Inhibition of tumor progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, Angagaw M, Laskey J, Bettano KA, Kasibhatla S, Reilly JF, Sur C, Majumder PK, Cancer Res 2009 69 7466 7472 10.1158/0008-5472.CAN-08-4385 19738074
95. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Posen N, Sawyers CL, Cancer Cell 2011 19 575 586 10.1016/j.ccr.2011.04.008 21575859
96. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and posttranscriptional increases in cyclin D proteins. Xu Y, Chen SY, Ross KN, Balk SP, Cancer Res 2006 66 7783 7791 10.1158/0008-5472.CAN-05-4472 16885382 (Pubitemid 44289239)
97. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minhas V, Lehman ML, Hendy SC, Buchanan G, Nelson CC, Rasko JE, Holst J, Cancer Res 2011 71 7525 7536 10.1158/0008-5472. CAN-11-1821 22007000
98. Metabolic signatures of malignant progression in prostate epithelial cells. Teahan O, Bevan CL, Waxman J, Keun HC, Int J Biochem Cell Biol 2011 43 1002 1009 10.1016/j.biocel.2010.07.003 20633696
99. Androgen receptor enhances p27 degradation in prostate cancer cells through rapid and selective TORC2 activation. Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, Swanson KD, Cai C, Balk SP, Yan X, J Biol Chem 2012 287 2090 2098 10.1074/jbc.M111.323303 22139837
100. Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin /p70 S6K pathway. Cao Y, Kamioka Y, Yokoi N, Kobayashi T, Hino O, Onodera M, Mochizuki N, Nakae J, J Biol Chem 2006 52 40242 40251 (Pubitemid 46041829)
101. FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Chen CC, Jeon SM, Bhaskar PT, Nogueira V, Sundararajan D, Tonic I, Park Y, Hay N, Dev Cell 2010 18 592 604 10.1016/j.devcel.2010.03.008 20412774
102. Hallmarks of cancer: the next generation. Hanahan D, Weinberg RA, Cell 2011 144 646 674 10.1016/j.cell.2011.02.013 21376230
103. Influence of amount of milk consumption on the rate of growth of school children. Orr JB, B Med J 1928 1 140 141 10.1136/bmj.1.3499.140
104. Cow's milk and linear growth in industrialized and developing countries. Hoppe C, Mølgaard C, Michaelsen KF, Annu Rev Nutr 2006 26 131 173 10.1146/annurev.nutr.26.010506.103757 16848703
105. Dairy and milk consumption and child growth: Is BMI involved? An analysis of NHANES 1999-2004. Wiley AS, Am J Hum Biol 2010 22 517 525 10.1002/ajhb.21042 20155844
106. Milk intake and total dairy consumption: associations with early menarche in NHANES 1999-2004. Wiley AS, PloS One 2011 6 14685 10.1371/journal.pone. 0014685 21347271
107. Evolutionary traits in human milk proteins. Bounous G, Kongshavn PA, Taveroff A, Gold P, Med Hypotheses 1988 27 133 140 10.1016/0306-9877(88)90158-2 3059144
108. Amino acid composition of human milk is not unique. Davis TA, Nguyen HV, Garcia-Bravo R, Fiorotto ML, Jackson EM, Lewis DS, Lee DR, Reeds PJ, J Nutr 1994 124 1126 1132 8027865 (Pubitemid 24226519)
109. Cow milk consumption, insulin-like growth factor-I, and human biology: a life history approach. Wiley AS, Am J Hum Biol 2012 24 130 138 10.1002/ajhb.22201 22121110
110. Milk protein intake, the metabolic-endocrine response, and growth in infancy: data from a randomized clinical trial. Socha P, Grote V, Gruszfeld D, Janas R, Demmelmair H, Closa-Monasterolo R, Escribano Subías J, Scaglioni S, Verduci E, Dain E, Langhendries JP, Perrin E, Koletzko B, for the European Childhood Obesity Trial Study Group, Am J Clin Nutr 2011 94 suppl 6 1776S 1784S 21849603
111. Protein intake in early infancy: effects on plasma amino acid concentrations, insulin metabolism, and growth. Axelsson IE, Ivarsson SA, Räihä NC, Pediatr Res 1989 26 614 617 2689986 (Pubitemid 20001670)
112. Leucine signaling in the pathogenesis of type 2 diabetes and obesity. Melnik BC, World J Diabetes 2012 3 38 53 10.4239/wjd.v3.i3.38 22442749
113. Excessive leucine-mTORC1-signalling of cow milk-based infant formula: the missing link to understand early childhood obesity. Melnik BC, J Obesity 2012 2012 197653
114. Fatty acid composition and energy density of foods available to African hominids. Evolutionary implications for human brain development. Cordain L, Watkins BA, Mann NJ, World Rev Nutr Diet 2001 90 144 161 11545040 (Pubitemid 33319127)
115. Differential regulation of insulin-like growth factor I (IGF-I) and IGF binding protein-1 messenger ribonucleic acids by amino acid availability and growth hormone in rat hepatocyte primary culture. Thissen JP, Pucilowska JB, Underwood LE, Endocrinology 1994 134 1570 1576 10.1210/en.134.3.1570 7509741 (Pubitemid 24085618)
116. Animal protein intake, serum insulin-like growth factor I, and growth in healthy 2.5-y-old Danish children. Hoppe C, Udam TR, Lauritzen L, Molgaard C, Juul A, Michaelsen KF, Am J Clin Nutr 2004 80 447 452 15277169
117. High intakes of skimmed milk, but not meat, increase serum IGF-I and IGFBP-3 in eight-year-old boys. Hoppe C, Molgaard C, Juul A, Michaelsen KF, Eur J Clin Nutr 2004 58 1211 1216 10.1038/sj.ejcn.1601948 15054433 (Pubitemid 39264017)
118. Differential effects ofcasein versus whey on fasting plasma levels of insulin, IGF-1 and IGF-1/IGFBP-3: results from a randomized 7-day supplementation study in prepubertal boys. Hoppe C, Molgaard C, Dalum C, Vaag A, Michaelsen KF, Eur J Clin Nutr 2009 63 1076 1083 10.1038/ejcn.2009.34 19471293
119. Impaired IGF1R signaling in cells expressing longevity-associated human IGF1R alleles. Tazearslan C, Hunag H, Barzilai N, Suh Y, Aging Cell 2011 10 551 554 10.1111/j.1474-9726.2011.00697.x 21388493
120. Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Steuerman R, Shevah O, Laron Z, Eur J Endocrinol 2011 164 485 489 10.1530/EJE-10-0859 21292919
121. Growth hormone receptor deficiency is associated with a major reduction in proaging signaling, cancer, and diabetes in humans. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wie M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohne P, Longo VD, Sci Transl Med 2011 3 70ra13 10.1126/scitranslmed.3001845 21325617
122. Clever cancer strategies with FoxO transcription factors. Maiese K, Chong ZZ, Shang YC, Hou J, Cell Cycle 2008 7 3829 3839 10.4161/cc.7.24.7231 19066462
123. Insulin-like growth factor-I and cancer mortality in older men. Major JM, Laughlin GA, Kritz-Silverstein D, Wingard DL, Barrett-Connor E, J Clin Endocrinol Metab 2010 95 1054 1059 10.1210/jc.2009-1378 20080855
124. Serum insulin-like growth factor-I levels and potential risk of type 2 diabetes. Dunger DB, Ong KK, Sandhu MS, Horm Res 2003 60 suppl 3 131 135 14671410 (Pubitemid 37548216)
125. Prostate carcinogenesis with diabetes and androgen-deprivation-therapy- related diabetes: an update. Hara N, Exp Diabetes Res 2012 2012 801610 22792092
126. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R, J Natl Cancer Inst 2000 92 1910 1907 10.1093/jnci/92.23.1910 11106682
127. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk:systematic review and meta-regression analysis. Renehan AG, Zwahlen M, Minder C, ODwyer ST, Shalet SM, Egger M, Lancet 2004 363 1353
128. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Clayton PE, Banerjee I, Murray PG, Renehan AG, Nature Rev Endocrinol 2011 7 11 24 10.1038/nrendo.2010.171
129. Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women. Norat T, Dossus L, Rinaldi S, Overvad K, Grønbaek H, Tjønneland A, Halkjær J, Dossus L, Boeing H, Kröger J, Trichopoulou A, Zylis D, Trichopoulos D, Boutron-Ruault MC, de Lauzon-Guillain B, Clavel-Chapelon F, Palli D, Berrino F, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Gram IT, Rodríguez L, Jakszyn P, Molina-Montes E, Navarro C, Barricarte A, Larrãaga N, Khaw KT, Rodwell S, Rinaldi S, Slimani N, Norat T, Gallo V, Riboli E, Kaaks R, Eur J Clin Nutr 2007 6 91 98 (Pubitemid 44921120)
130. The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition. Crowe FL, Key TJ, Allen NE Appleby PN, Roddam A, Overvad K, Grønbaek H, Tjønneland A, Halkjaer J, Dossus L, Boeing H, Kröger J, Trichopoulou A, Dilis V, Trichopoulos D, Boutron-Ruault MC, De Lauzon B, Clavel-Chapelon F, Palli D, Berrino F, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Vrieling A, van Gils CH, Peeters PH, Gram IT, Skeie G, Lund E, Rodríguez L, Jakszyn P, Molina- Montes E, Tormo MJ, Barricarte A, Larrãaga N, Khaw KT, Bingham S, Rinaldi S, Slimani N, Norat T, Gallo V, Riboli E, Kaaks R, Cancer Epidemiol Biomarkers Prev 2009 18 1333 1340 10.1158/1055-9965.EPI-08-0781 19423514
131. A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. Young NJ, Metcalfe C, Gunnell D, Rowlands MA, Lane JA, Gilbert R, Avery KNL, Davis M, Neal DE, Hamdy FC, Donovan J, Martin RM, Holly JMP, Cancer Causes Control 2012 23 907 917 10.1007/s10552-012-9961-6 22527168
132. Molecular interactions of the IGF system. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE, Cytokine Growth Factor Rev 2005 16 421 439 10.1016/j.cytogfr.2005.04.004 15936977 (Pubitemid 41022012)
133. Over-stimulation of insulin/IGF-1 signaling by Western diet promotes diseases of civilization: lessons learnt from Laron syndrome. Melnik BC, John SM, Schmitz G, Nutr Metab (Lond) 2011 8 41 10.1186/1743-7075-8-41
134. Branched-chain amino acids are essential in the regulation of PHAS-I and p70 S6 kinase by pancreatic -cells. A possible role in protein translation and mitogenic signaling. Xu G, Kwon G, Marsahll CA, Lin TA, Lawrence JC, McDaniel ML, J Biol Chem 1998 273 18178 28184
135. Leucine metabolism in regulation of insulin secretion from pancreatic beta cells. Yang J, Chi Y, Burkhardt BR, Guan Y, Wolf BA, Nutr Rev 2010 68 270 279 10.1111/j.1753-4887.2010.00282.x 20500788
136. Metabolic and autocrine regulation of the mammalian target of rapamycin by pancreatic beta-cells. McDaniel ML, Marshall CA, Pappan KL, Kwon G, Diabetes 2002 51 2877 2885 10.2337/diabetes.51.10.2877 12351422
137. Metabolic regulation by leucine of translation initiation through the mTOR-signaling pathway by pancreatic beta-cells. Xu G, Kwon G, Cruz WS, Marshall CA, McDaniel ML, Diabetes 2001 50 353 360 10.2337/diabetes.50.2.353 11272147 (Pubitemid 32127292)
138. Milk consumption and the prepubertal somatotropic axis. Rich-Edwards JW, Ganmaa D, Pollak MN, Nakamoto EK, Kleinman K, Willett WC, Frazier A, Tserendolgor, Nutr J 2007 6 28 10.1186/1475-2891-6-28 17900364 (Pubitemid 350209637)
139. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. Nilsson M, Holst JJ, Björck IM, Am J Clin Nutr 2007 85 996 1004 17413098 (Pubitemid 46557914)
140. Dissociation of the glycaemic and insulinaemic responses to whole and skimmed milk. Hoyt G, Hickey MS, Cordain L, Br J Nutr 2005 93 175 177 10.1079/BJN20041304 15788109
141. The insulinogenic effect of whey protein is partially mediated by a direct effect of amino acids and GIP on beta-cells. Salehi A, Gunnerud U, Muhammed SJ, Ostman E, Holst JJ, Björck I, Rorsman P, Nutr Metab (Lond) 2012 9 1 48 10.1186/1743-7075-9-48
142. Protein hydrolysate/leucine co-ingestion reduces the prevalence of hyperglycemia in type 2 diabetic patients. Manders RJ, Prate SF, Meex RC, Koopman R, de Roos AL, Wagenmakers AJ, Saris WH, van Loon LJ, Diabetes Care 2006 29 2721 2722 10.2337/dc06-1424 17130211 (Pubitemid 44912205)
143. High intakes of milk, but not meat, increase s-insulin and insulin resistance in 8-year-old boys. Hoppe C, Mølgaard C, Vaag A, Barkholt V, Michaelsen KF, Eur J Clin Nutr 2005 59 393 398 10.1038/sj.ejcn.1602086 15578035 (Pubitemid 40403293)
144. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Zick Y, Sci STKE 2005 268 e4
145. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH, Pollak M, J Natl Cancer Inst 2007 99 1793 1800 10.1093/jnci/djm231 18042933 (Pubitemid 351767208)
146. Insulin analogues diplay IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells. Weinstein D, Simon M, Yeheezkel E, Laron Z, Werner H, Diabetes Metab Res Rev 2009 25 41 49 10.1002/dmrr.912 19145584
147. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor-I levels. Moore T, Carbajal S, Beltran L, Perkins SN, Yakar S, LeRoith D, Hursting SD, DiGiovanni J, Cancer Res 2008 68 3680 3688 10.1158/0008-5472.CAN-07-6271 18483250
148. Dietary energy balance modulates signalling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues. Moore T, Beltran L, Carbajal S, Strom S, Traag J, Husting SD, DiGiovanni J, Cancer Prev Res 2008 1 65 76 10.1158/1940-6207.CAPR-08-0022
149. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Zhu ML, Kyrianou N, Endocr Relat Cancer 2008 15 841 849 10.1677/ERC-08-0084 18667687
150. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentrations in humans. Fontana L, Weiss EP, Villareal DT, Klein S, Holloszy JO, Aging Cell 2008 7 681 687 10.1111/j.1474-9726.2008.00417.x 18843793
151. Whey protein ingestion activates mTOR-dependent signalling after resistance exercise in young men: A double-blinded randomized controlled trial. Farnfield MM, Carey KA, Gran P, Trenerry MK, Cameron-Smith D, Nutrients 2009 1 263 275 10.3390/nu1020263 22253983
152. Oral leucine administration stimulates protein synthesis in rat skeletal muscle. Crozier SJ, Kimball SR, Emmert SW, Anthony JC, Jefferson LS, J Nutr 2005 135 376 382 15735066 (Pubitemid 40365191)
153. Amino acids regulate skeletal muscle PHAS-I and p70S6-kinase phosphorylation independently of insulin. Long W, Saffer L, Wei L, Barrett EJ, Am J Physiol Endocrinol Metab 2000 279 301 306
154. Regulation of 4E-BP1 phosphorylation: a novel two- step mechanism. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N, Genes Dev 1999 13 1422 1437 10.1101/gad.13.11.1422 10364159 (Pubitemid 29270247)
155. Protein quality assessment: impact of expanding understanding of protein and amino acid needs for optimal health. Millward DJ, Layman DK, Tomé D, Schaafsma G, Am J Clin Nutr 2008 87 1576S 1581S 18469291 (Pubitemid 351679814)
156. An insulin index of foods: the insulin demand generated by 1000-kJ portions of common foods. Holt S, Brand Miller J, Petocz P, Am J Clin Nutr 1997 66 1264 1276 9356547 (Pubitemid 27473353)
157. Metabolic and physiologic improvements from consuming a paleolithic, hunter-gatherer type diet. Frassetto LA, Schloetter M, Mietus-Synder M, Morris RC Jr, Sebastian A, Eur J Clin Nutr 2009 63 947 955 10.1038/ejcn.2009.4 19209185
158. Is cows milk harmful to a childs health? Agostoni C, Turck D, J Pediatr Gastroenterol Nutr 2011 53 594 600 21921812
159. Estrogen: one of the risk factors in milk for prostate cancer. Qin LQ, Wang PY, Kaneko T, Hoshi K, Sato A, Med Hypotheses 2004 62 133 142 10.1016/S0306-9877(03)00295-0 14729019 (Pubitemid 38200020)
160. Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy. Kruithof-Dekker IG, Tetu B, Janssen PJ, Van der Kwast TH, J Urol 1996 156 1194 1197 10.1016/S0022-5347(01)65749-5 8709345 (Pubitemid 26269855)
161. Naturally occurring estrogens in processed milk and in raw milk (from gestated cows). Malekinejad H, Scherpenisse P, Bergwerff AA, J Agric Food Chem 2006 54 9785 9791 10.1021/jf061972e 17177502 (Pubitemid 46158971)
162. Quantitative measurement of endogenous estrogen metabolites, risk-factors for development of breast cancer, in commercial milk products by LC-MS/MS. Farlow DW, Xu X, Veenstra TD, J Chromatography B Analyt Technol Biomed Life Sci 2009 877 1327 1334 10.1016/j.jchromb.2009.01.032
163. Acne, dairy and cancer. The 5alpha-P link. Danby FW, Dermatoendocrinology 2009 1 9 13
164. Exposure to exogenous estrogen through intake of commercial milk produced from pregnant cows. Maruyama K, Oshima T, Ohyama K, Pediatr Internat 2010 52 33 38 10.1111/j.1442-200X.2009.02890.x
165. Developmental estrogenization and prostatic neoplasia. Santti R, Newbold RR, Makela S, Pylkkanen L, Mclachlan JA, Prostate 1994 24 67 78 10.1002/pros.2990240204 7508622 (Pubitemid 24073105)
166. Hormones and prostate carcinogenesis: Androgens and estrogens. Bosland MC, Mahmoud AM, J Carcinog 2011 10 33 10.4103/1477-3163.90678 22279418
167. Comparison of spontaneous and experimentally induced canine prostatic hyperplasia. DeKlerk DP, Coffey DS, Ewing LL, McDermott IR, Reiner WG, Robinson CH, Scott WW, Strandberg JD, Talalay P, Walsh PC, Wheaton LG, Zirkin BR, J Clin Invest 1979 64 842 849 10.1172/JCI109532 89121 (Pubitemid 10223765)
168. Similarities of prostate and breast cancer: Evolution, diet, and estrogens. Coffey DS, Urology 2001 57 Suppl 4A 31 33 11295592
169. Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score. Torlakovic E, Lilleby W, Torlakovic G, Fosså SD, Chibbar R, Hum Pathol 2002 33 646 651 10.1053/hupa.2002.124033 12152165 (Pubitemid 34827547)
170. Molecular markers for predicting prostate cancer stage and survival. Dunsmuir WD, Gillett CE, Meyer LC, Young MP, Corbishley C, Eeles RA, Kirby RS, BJU Int 2000 86 869 878 11069416
171. Estrogen receptor beta expression in prostate adenocarcinoma. Asgari M, Morakabati A, Diagn Pathol 2011 6 61 10.1186/1746-1596-6-61 21733187
172. L-leucine transport in human breast cancer cells (MCF-7 and MDA-MB-231): kinetics, regulation by estrogen and molecular identity of the transporter. Shennan DB, Thomson J, Gow IF, Travers MT, Barber MC, Biochim Biophys Acta 2004 1664 206 216 10.1016/j.bbamem.2004.05.008 15328053 (Pubitemid 39140994)
173. Low-fat milk promotes the development of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in rats. Qin LQ, Xu JY, Wang PY, Ganmaa D, Li J, Wang J, Kaneko T, Hoshi K, Shirai T, Sato A, Int J Cancer 2004 110 491 496 10.1002/ijc.20172 15122580 (Pubitemid 38658013)
174. Promoting effects of milk on the development of 7,12-diemethylbenz(a) anthracene (DMBA)-induced mammary tumors in rats. Ma DF, Katoh R, Zhou H, Wang PY, Acta Histochem Cytochem 2007 40 61 67 10.1267/ahc.07008 17576434 (Pubitemid 46743503)
175. Commercial cowsmilk has uterotrophic activity on the uteri of young ovariectomized rats and immature rats. Ganmaa D, Tezuka H, Enkhmaa D, Hoshi K, Sato A, Int J Cancer 2006 118 2363 2365 10.1002/ijc.21659 16331633
176. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. Chang SB, Miron P, Miron A, Iglehart JD, J Surg Res 2007 138 37 44 10.1016/j.jss.2006.07.003 17109887 (Pubitemid 46227456)
177. Diet, obesity, and prostate health: Are we missing the link? Tewari R, Rajender S, Natu SM, Dalela D, Goel A, Goel MM, Tandon P, J Androl 2012 Feb 9 Epubahead of print
178. Total food consumption and body mass index in relation to prostate cancer risk: a case-control study in Sweden with prospectively collected exposure data. Gronberf H, Damber L, Damber JE, J Urol 1996 155 969 974 10.1016/S0022-5347(01)66360-2 8583620 (Pubitemid 26052692)
179. Obesity and prostate cancer: making sense out of apparently conflicting data. Freeland SJ, Platz EA, Epidemiol Rev 2007 29 88 97 10.1093/epirev/mxm006 17478439 (Pubitemid 47229642)
180. Obesity, diabetes and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR, Cancer Epidemiol Biomarkers Prev 2006 15 1977 1983 10.1158/1055-9965.EPI-06-0477 17035408 (Pubitemid 44664277)
181. Body mass index and incidence of localized andadvanced prostate cancer-a dose-response meta-analysis of prospective studies. Discacciati A, Orsini N, Wolk A, Ann Oncol 2012 Jan 6 [Epub ahead of print]
182. Obesity, body composition, and prostate cancer. Fowke JH, Motley SS, Concepcion RS, Penson DF, Barocas DA, BMC Cancer 2012 12 23 10.1186/1471-2407- 12-23 22257467
183. Regulation of amino acid- sensitive TOR signaling by leucine analogues in adipocytes. Lynch CJ, Fox HL, Vary TC, Jefferson LS, Kimball SR, J Cell Biochem 2000 77 234 251 10.1002/(SICI)1097-4644(20000501)77:2<234::AID-JCB7>3.0. CO;2-I 10723090 (Pubitemid 30176653)
184. Role of leucine in the regulation of mTOR by amino acids: revelations from structure-activity studies. Lynch CJ, J Nutr 2001 131 861S 865S 11238775 (Pubitemid 32199160)
185. Assessment of cell-signaling pathways in the regulation of mammalian target of rapamycin (mTOR) by amino acids in rat adipocytes. Pham PT, Heydrick SJ, Fox HL Kimball SR, Jefferson LS Jr, Lynch CJ, J Cell Biochem 2000 79 427 441 10.1002/1097-4644(20001201)79:3<427::AID-JCB80>3.0.CO;2-0 10972980
186. Regulation of peroxisome proliferator-activated receptor- activity by mammalian target of rapamycin and amino acids in adipogenesis. Kim JE, Chen J, Diabetes 2004 53 2748 2756 10.2337/diabetes.53.11.2748 15504954 (Pubitemid 39425899)
187. Amino acids stimulate phosphorylation of p70S6k and organization of rat adipocytes into multicellular clusters. Fox HL, Kimball SR, Jefferson LS, Lynch CJ, Am J Physiol Cell Physiol 1998 274 206 C213
188. Amino acid effects on translational repressor 4E-BP1 are mediated primarily by L-leucine in isolated adiopocytes. Fox HL, Pham PT, Kimball SR, Jefferson LS, Lynch CJ, Am J Physiol Cell Physiol 1998 275 1232 C1238
189. S6K1 plays a critical role in early adipocyte differentiation. Carnevalli LS, Masuda K, Frigerio F, Le Bacquer O, Um SH, Gandin V, Topisirovic I, Sonenberg N, Thomas G, Kozma SC, Dev Cell 2010 18 763 774 10.1016/j.devcel.2010. 02.018 20493810
190. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Boura-Halfon S, Zick Y, Am J Physiol Endocrinol Metab 2009 296 581 E591 10.1152/ajpendo.90437.2008 18728222
191. The mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Krebs M, Brunmair B, Brehm A, Artwohl M, Szendroedi J, Nowotny P, Roth E, Fürnsinn C, Promintzer M, Anderwald C, Bischof M, Roden M, Diabetes 2007 56 1600 1607 10.2337/db06-1016 17329620 (Pubitemid 46842618)
192. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Tremblay F, Krebs M, Dombrowski L, Brehm A, Bernroider E, Roth E, Nowotny P, Waldhäusl W, Marette A, Roden M, Diabetes 2005 54 2674 2684 10.2337/diabetes.54.9.2674 16123357 (Pubitemid 41233590)
193. Hyperinsulin response to oral leucine in obesity and acromegaly. Johnson S, Karam JH, Levin SR, Grodsky GM, Forsham PH, J Clin Endocrinol Metab 1973 37 431 435 10.1210/jcem-37-3-431 4785430
194. Diet-induced hyperinsulinemia accelerates growth of androgen-independent PC-3 cells in vitro. Vikram A, Jena G, Nutr Cancer 2012 64 121 127 10.1080/01635581.2012.630556 22171530
195. Plasma amino acid levels and insulin secretion in obesity. Felig P, Marliss E, Cahill GF Jr, N Engl J Med 1969 281 811 816 10.1056/ NEJM196910092811503 5809519
196. Metabolic fate of leucine: a significant sterol precursor in adipose tissue and muscle. Rosenthal J, Angel A, Farkas J, Am J Physiol 1974 226 411 418 4855772
197. Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. She P, Van Horn C, Reid T, Hutson SM, Cooney RN, Lynch CJ, Am J Physiol Endocrinol Metab 2007 293 1552 E1563 10.1152/ajpendo.00134.2007 17925455 (Pubitemid 350255104)
198. Adipose tissue branched chain amino acid (BCAA) metabolism modulates circulating BCAA levels. Herman MA, She P, Peroni OD, Lynch CJ, Kahn BB, J Biol Chem 2010 285 11348 11356 10.1074/jbc.M109.075184 20093359
199. Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. She P, Reid TM, Bronson SK, Vary TC, Hajnal A, Lynch CJ, Hutson SM, Cell Metab 2007 6 181 194 10.1016/j.cmet.2007.08.003 17767905 (Pubitemid 47324140)
200. Autophagy and cancer - issues we need to digest. Liu EY, Ryan KM, J Cell Sci 2012 125 2349 2358 10.1242/jcs.093708 22641689
201. Systems biology of the autophagy- lysosomal pathway. Jegga AG, Schneider L, Ouyang X, Zhang J, Autophagy 2011 5 477 489
202. Role of autophagy in cancer: management of metabolic stress. Jin S, White E, Autophagy 2007 3 28 31 16969128 (Pubitemid 46100707)
203. Autophagy and cancer cell metabolism. Lozy F, Karantza V, Sem Cell Dev Biol 2012 23 395 401 10.1016/j.semcdb.2012.01.005
204. Nutrient-dependent regulation of autophagy through the target of rapamycin pathway. Chang YY, Juhász G, Goraksha-Hicks P, Arsham AM, Mallin DR, Muller LK, Neufeld TP, Biochem Soc Trans 2009 37 232 236 10.1042/BST0370232 19143638
205. Role of autophagy in cancer. Mathew R, Karantza-Wadsworth V, White E, Nat Rev Cancer 2007 7 961 967 10.1038/nrc2254 17972889 (Pubitemid 350165856)
206. Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy. DiPaola RS, Dvorzhinski D, Thalasila A, Garikapaty V, Doram D, May M, Bray K, Mathew R, Beaudoin B, Karp C, Stein M, Foran DJ, White E, Prostate 2008 68 1743 1752 10.1002/pros.20837 18767033
207. Autophagy and cancer cell metabolism. Lozy F, Karantza V, Semin Cell Dev Biol 2012 Jan 18 [Epub ahead of print]
208. Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells. Kaini RR, Sillerud LO, Zhaorigetu S, Hu CA, Prostate 2012 Epub ahead of print 10.1002/pros.22489
209. Amino acid regulation of autophagosome formation. Meijer AJ, Methods Mol Biol 2008 445 89 109 10.1007/978-1-59745-157-4-5 18425444
210. Reconstitution of leucine-mediated autophagy via the mTORC1 -Barkor pathway in vitro. Yan X, Sun Q, Ji J, Zhu Y, Liu Z, Zhong Q, Autophagy 2012 8 213 221 10.4161/auto.8.2.18563 22258093
211. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, Gi YJ, Lu B, Cancer Res 2006 66 10040 10047 10.1158/0008-5472.CAN-06-0802 17047067 (Pubitemid 44672057)
212. Monascuspiloin enhances the radiation sensitivity of human prostate cancer cells by stimulating endoplasmic reticulum stress and inducing autophagy. Chiu HW, Fang WH, Chen YL, Wu MD, Yuan MD, Ho SY, Wang YJ, PLoS ONE 2012 7 40462 10.1371/journal.pone.0040462 22802963
213. Reduction of insulin signalling pathway IRS-1/IRS-2/AKT/mTOR and decrease of epithelial cell proliferation in the prostate of glucocorticoid-treated rats. Costa MM, Violato NM, Taboga SR, Gáes RM, Bosqueiro JR, Int J Exp Pathol 2012 93 188 195 10.1111/j.1365-2613.2012.00817.x 22583132
214. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Shimizu N, Yoshikawa N, Ito N, Maruyama T, Suzuki Y, Takeda S, Nishitani S, Takehana K, Sano M, Fukuda K, Suematsu M, Morimoto C, Tanaka H, Cell Metab 2011 13 170 182 10.1016/j.cmet.2011.01.001 21284984
215. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr, Genes Dev 2004 18 2893 2904 10.1101/gad.1256804 15545625 (Pubitemid 39602308)
216. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW, Genes Dev 2008 22 239 251 10.1101/gad.1617608 18198340
217. Dexamethasone represses signaling through the mammalian target of rapamycin muscle cells by enhancing expression of REDD1. Wang H, Kubica N, Ellisen LW, Jefferson LS, Kimball SR, J Biol Chem 2006 281 39128 39134 10.1074/jbc.M610023200 17074751 (Pubitemid 46041872)
218. Regulation of gluconeogenesis by Krüppel-like factor 15. Gray S, Wang B, Orihuela Y, Hong EG, Fisch S, Haldar S, Cline GW, Kim JK, Peroni OD, Kahn BB, Jain MK, Cell Metab 2007 5 305 312 10.1016/j.cmet.2007.03.002 17403374 (Pubitemid 46477856)
219. Metformin in prostate cancer: two for the price of one. Clements A, Gao B, Yeap SHO, Wong MKY, Ali SS, Gurney H, Ann Oncol 2011 22 2556 2560 10.1093/annonc/mdr037 21421541
220. Mortality after incident cancer in people with and without type 2 diabetes. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL, Diabetes Care 2012 35 299 304 10.2337/dc11-1313 22266734
221. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. He XX, Tu SM, Lee MH, Yeung SC, Ann Oncol 2011 22 2640 2645 10.1093/annonc/mdr020 21415239
222. The antidiabetic drug metformin exerts an antitumorial effect in vitro and in vivo through a decrease of cyclin D1 level. Ben Sahra I, Laurent K, Loubat A, Giorgett-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F, Oncogene 2008 27 3576 3586 10.1038/sj.onc.1211024 18212742 (Pubitemid 351793803)
223. Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. Hardie DG, FEBS Lett 2008 582 81 89 10.1016/j.febslet.2007.11.018 18022388 (Pubitemid 350297243)
224. cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity. Xie J, Ponuwei GA, Moore CE, Willars GB, Tee AR, Herbert TP, Cell Signal 2011 23 1927 1935 10.1016/j.cellsig.2011.06.025 21763421
225. Targeting cancer cell metabolism: the combination of metformin and 2-dexoyglucose induces p53-dependent apoptosis in prostate cancer cells. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand- Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti JF, Bost F, Cancer Res 2010 70 2465 2475 10.1158/0008-5472.CAN-09-2782 20215500
226. Metformin, independent of AMPK, inhibits mTORC1 in a RAG GTPase-dependent manner. Kalender A, Selvaraj A, Kim SY, Gulati P, Brlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G, Cell Metab 2010 11 390 398 10.1016/j.cmet.2010.03.014 20444419
227. Regulation of TORC1 by Rag GTPases in nutrient response. Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL, Nat Cell Biol 2008 10 935 945 10.1038/ncb1753 18604198
228. Role of diet in prostate cancer development and progression. Chan JM, Gann PH, Giovannucci EL, J Clin Oncol 2005 23 8152 8160 10.1200/JCO.2005.03.1492 16278466 (Pubitemid 46211548)
229. Impact of diet on prostate cancer: a review. Sonn GA, Aronson W, Litwin MS, Prostate Cancer Prostatic Dis 2005 8 304 310 10.1038/sj.pcan.4500825 16130015 (Pubitemid 43078163)
230. Association of energy, fat, calcium, and vitamin D with prostate cancer risk. Kristal AR, Cohen JH, Qu P, Stanford JL, Cancer Epidemiol Biomarkers Prev 2002 11 719 725 12163324 (Pubitemid 34851905)
231. Intake of carotenoids and retinol in relation to risk of prostate cancer. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC, J Natl Cancer Inst 1995 87 1767 1776 10.1093/jnci/87.23.1767 7473833
232. Diet in the epidemiology of carcinoma of the prostate gland. Graham S, Haughey B, Marshall J, Priore R, Byers T, Rzepka T, Mettlin C, Pontes JE, J Natl Cancer Inst 1983 70 687 692 6572757 (Pubitemid 13137150)
233. Vegetables, fruits, legumes and prostate cancer: a multi-ethnic case-control study. Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallaher RP, Wilkens LR, John EM, Howe GR, Dreon DM, West DW, Paffenbarger RS, Cancer Epidemiol Biomarkers Prev 2000 9 795 804 10952096 (Pubitemid 30660052)
234. Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Marques FZ, Markus MA, Morris BJ, Int J Biochem Cell Biol 2009 41 2125 2128 10.1016/j.biocel.2009.06.003 19527796
235. Updates of mTOR inhibitors. Zhou H, Luo Y, Huang S, Anticancer Agents Med Chem 2010 10 571 581 20812900
236. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. Jiang H, Shang X, Wu H, Gautam SC, Al-Holou S, Li C, Kuo J, Zhang L, Chopp M, J Exp Ther Oncol 2009 8 25 33 19827268
237. Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells. Brito PM, Devillard R, Negre-Salvayre A, Almeida LM, Dinis TC, Salvayre R, Augé N, Atherosclerosis 2009 205 126 134 10.1016/j.atherosclerosis.2008.11.011 19108833
238. Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. Lin JN, Lin VC, Rau KM, Shieh PC, Kuo DH, Shieh JC, Chen WJ, Tsai SC, Way TD, J Agric Food Chem 2010 58 1584 1592 10.1021/jf9035782 19928762
239. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Fröjdjö S, Cozzone D, Vidal H, Pirola L, Biochem J 2007 406 511 518 10.1042/BJ20070236 17550345 (Pubitemid 47425457)
240. Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3 K/Akt signaling pathways. Zhang Q, Kelly AP, Wang L, French SW, Tang X, Duong HS, Messadi DV, Le AD, J Invest Dermatol 2006 126 2607 2613 10.1038/sj.jid.5700472 16841034 (Pubitemid 44764044)
241. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. Van Aller GS, Carson JD, Tang W, Peng H, Zhao L, Copeland RA, Tummino PJ, Luo L, Biochem Biophys Res Commun 2011 406 194 199 10.1016/j.bbrc.2011.02.010 21300025
242. Curcumin disrupts the mammalian target of rapamycin-raptor complex. Beevers CS, Chen L, Liu L, Luo Y, Webster NJ, Huang S, Cancer Res 2009 69 1000 1008 10.1158/0008-5472.CAN-08-2367 19176385
243. Evidence that low- dose, long-term genistein treatment inhibits oestradiol-stimulated growth in MCF-7 cells by down-regulation of the PI3-kinase/Akt signalling pathway. Anastasius N, Boston S, Lacey M, Storing N, Whitehead SA, J Steroid Biochem Mol Biol 2009 116 50 55 10.1016/j.jsbmb.2009.04. 009 19406242
244. A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Nakamura Y, Yogosawa S, Izutani Y, Watanabe H, Otsuji E, Sakai T, Mol Cancer 2009 8 100 10.1186/1476-4598-8-100 19909554
245. Mammalian target of rapamycin repression by 3,3-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Kong D, Banerjee S, Huang W, Li Y, Wang Z, Kim HR, Sarkar FH, Cancer Res 2008 68 1927 1934 10.1158/0008-5472.CAN-07-3241 18339874 (Pubitemid 351416579)
246. Caffeine targets TOR complex I and provides evidence for a regulatory link between the FRB and kinase domains of Tor1p. Reinke A, Chen JC, Aronova S, Powers T, J Biol Chem 2006 281 31616 31626 10.1074/jbc.M603107200 16923813 (Pubitemid 46043262)
247. Curcumin as Curecumin: from kitchen to clinic. Goel A, Kunnumakkara AB, Aggarwal BB, Biochem Pharmacol 2008 75 787 809 10.1016/j.bcp.2007.08.016 17900536 (Pubitemid 351181424)
248. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Johnson SM, Gulhati P, Arrieta I, Wang X, Uchida T, Gao T, Evers BM, Anticancer Res 2009 29 3185 3190 19661333
249. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Beevers CS, Li F, Liu L, Huang S, Int J Cancer 2006 119 757 764 10.1002/ijc.21932 16550606 (Pubitemid 44051438)
250. Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic. Banerjee S, Kong D, Wang Z, Bao B, Hillman GG, Sarkar FH, Mutat Res 2011 728 47 66 10.1016/j.mrrev.2011.06. 001 21703360
251. New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Connors SK, Chornokur G, Kumar NB, Nutr Cancer 2012 64 4 22 10.1080/01635581.2012.630158 22098273
252. Chemopreventive effects of tea in prostate cancer: green tea versus black tea. Henning SM, Wang P, Heber D, Mol Nutr Food Res 2011 55 905 920 10.1002/mnfr.201000648 21538852
253. Cancer prevention by tea: Evidence from laboratory studies. Yang CS, Wang H, Li GX, Yang Z, Guan F, Jin H, Pharmacol Res 2011 64 113 122 10.1016/j.phrs.2011.03.001 21397027
254. Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption. Henning SM, Aronson W, Niu Y, Conde F, Lee NH, Seeram NP, Lee RP, Lu J, Harris DM, Moro A, Hong J, Pak-Shan L, Barnard RJ, Ziaee HG, Csathy G, Go VL, Wang H, Heber D, J Nutr 2006 136 1839 1843 16772446 (Pubitemid 43973585)
255. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. Chen Q, Ganapathy S, Singh KP, Shankar S, Srivastava RK, PloS ONE 2010 5 15288 10.1371/journal.pone.0015288 21179458
256. Milk consumption during pregnancy is associated with increased size at birth: prospective cohort study. Olsen SF, Halldorsson TI, Willett WC, Knudsen VK, Gillman MW, Mikkelsen TB, Olsen J, and the NUTRIX Consortium, Am J Clin Nutr 2007 86 1104 1110 17921389 (Pubitemid 47538314)
257. Placental mTOR links maternal nutrient availability to fetal growth. Roos S, Powell TL, Jansson T, Biochem Soc Trans 2009 37 295 298 10.1042/BST0370295 19143650
258. Regulation of amino acid transporters by glucose and growth factors in cultured primary human trophoblast cells is mediated by mTOR singaling. Roos S, Lagerlöf O, Wennergren M, Powell TL, Jansson T, Am J Physiol Cell Physiol 2009 297 723 C731 10.1152/ajpcell.00191.2009 19587219
259. PI3K/mTOR signaling regulates prostatic branching morphogenesis. Ghosh S, Lau H, Simons BW, Powell JD, Meyers DJ, De Marzo AM, Berman DM, Lotan TL, Dev Biol 2011 360 329 342 10.1016/j.ydbio.2011.09.027 22015718
260. mTOR signaling and human cancer. Chantaravisoot N, Tamanoi F, The Enzymes 2010 28 301 316
261. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC, Prostate Cancer Prostatic Dis 2005 8 108 118 10.1038/sj.pcan.4500776 15724144 (Pubitemid 43118073)
262. Novel therapeutic molecular targets for prostate cancer: the mTOR signaling pathway and epidermal growth factor receptor. Tolcher AW, J Urol 2004 171 41 S44 10.1097/01.ju.0000108100.53239.b7 14713752 (Pubitemid 38090421)
263. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Morgan TM, Koreckij TD, Corey E, Curr Cancer Drug Target 2009 9 237 249 10.2174/156800909787580999
264. Combination of PI3K/mTOR inhibitors: Antitumor activity and molecular correlates. Mazzoletti M, Bortolin F, Brunelli L, Pastorelli R, Di Giandomenico S, Erba E, Ubezio P, Broggini M, Cancer Res 2011 71 4573 4584 10.1158/0008-5472.CAN-10-4322 21602434
265. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Wang Y, Kresiberg JI, Ghosh PM, Curr Cancer Drug Targets 2007 7 591 604 10.2174/156800907781662248 17896924 (Pubitemid 47358145)
266. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Parkin DM, Br J Cancer 2011 105 2 S5 22158314
267. Do diet and androgens alter prostate cancer risk via a common etiologic pathway? Ross RK, Henderson BE, J Nat Cancer Inst 1994 86 252 254 10.1093/jnci/86.4.252 8158675
268. Hyperinsulinemic diseases of civilization: more than just Sysdrome X. Cordain L, Eades MR, Eades MD, Comp Biochem Physiol A Mol Integr Physiol 2003 136 95 112 10.1016/S1095-6433(03)00011-4 14527633 (Pubitemid 37289410)
269. Paleolithic nutrition. A consideration of its nature and current implications. Eaton SB, Konner M, N Engl J Med 1985 312 283 289 10.1056/NEJM198501313120505 2981409 (Pubitemid 15199367)
270. Origins and evolution of the Western diet: health implications for the 21st century. Brand-Miller J, Am J Clin Nutr 2005 81 341 354 15699220 (Pubitemid 43078368)
271. The western diet and lifestyle and diseases of civilization. Carrera-Bastos P, Fontes-Villalba M, OKeefe JH, Lindeberg S, Cordain L, Res Rep Clin Cardiol 2011 2 15 35
272. From breast to bottle: a history of modern infant feeding. Bryder L, Endeavour 2009 33 54 59 10.1016/j.endeavour.2009.04.008 19464060
273. Androgen abuse in the community. Melnik BC, Curr Opin Endocrinol Diabetes Obes 2009 16 218 223 10.1097/MED.0b013e32832afdfe 19373082